Anticonvulsant agent 7
Anticonvulsant agent 7 is an orally active, broad-spectrum anticonvulsant that does not rely on direct blockade of Na+/Ca2+ channels. Anticonvulsant agent 7 can be used in seizure research[1].
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C17H23N3O3
- Masse moléculaire:317.38
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Calcium Channel
More
Activité biologique
Anticonvulsant agent 7 (30-300 mg/kg; i.p.; single administration) protects mice against scPTZ (absence/myoclonic)-induced seizures[1].
Anticonvulsant agent 7 (i.p.; single administration) has an ED50 of 11.1 mg/kg against psychomotor seizures induced by 6 Hz (32 mA), with a protective index > 9.0[1].
Anticonvulsant agent 7 (i.p.; single administration) has an ED50 of 40.9 mg/kg against drug-resistant seizures induced by 6 Hz (44 mA), with a protective index > 2.5[1].
Anticonvulsant agent 7 (30 mg/kg; p.o.; single administration) protects up to 100% of rats against MES-induced seizures, with the peak protective effect achieved at 0.5 h post-administration[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CF1 mice (male); CD-1 mice (male, 20-26 g)[1]
-
Dosage:30 mg/kg; 100 mg/kg; 300 mg/kg (preliminary screening); 26.3 mg/kg (ED50 determination)
-
Administration:i.p.; single dose
-
Result:Protected 100% of mice at 0.5 h and 4 h post-administration.
Achieved a median effective dose (ED50) of 26.3 mg/kg (i.p.).
Demonstrated a protective index (PI) of >3.8 relative to neurotoxicity (TD50 >100 mg/kg).
-
Animal Model:CF1 mice (male); CD-1 mice (male, 20-26 g)[1]
-
Dosage:30 mg/kg; 100 mg/kg; 300 mg/kg
-
Administration:i.p.; single dose
-
Result:Protected 100% of mice at 0.5 h and 4 h post-administration at 100 mg/kg (i.p.).
-
Animal Model:Sprague-Dawley rats (male, albino)[1]
-
Dosage:30 mg/kg
-
Administration:p.o.; single dose
-
Result:Protected 50% of rats at 0.25 h post-administration.
Protected 100% of rats at 0.5 h post-administration.
Protected 75% of rats at 1 h post-administration.
Protected 50% of rats at 2 h post-administration.
Protected 50% of rats at 3 h post-administration.
Chemical Information
-
Masse moléculaire 317.38
-
Formule C17H23N3O3
-
SMILES
O=C1N(CN2CCOCC2)C(C(C3=CC=CC=C3)(C(C)C)N1)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anticonvulsant agent 7 Related Classifications
HY-170801 Related Classifications
Powered by Bioz
- Anticonvulsant agent 7
- Anticonvulsant agent7
- Anticonvulsant agent-7
- Calcium Channel
- Sodium Channel
- mice
- MES-induced seizures
- pharmacoresistant seizures
- rats
- scPTZ-induced seizures
- oxaliplatin-induced tactile allodynia
- L-type Ca2+ channels
- L-type Na+ channels
- psychomotor seizures
- oxaliplatin-induced neuropathic pain
- Inhibitor
- inhibitor
- inhibit